ITN

OIPE JC16 APR 11 2005 PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liang et al.

Attorney Docket No.: TRNDP011

Application No.: 10/683,579

Examiner: Unassigned

Filed: October 9, 2003

Group: 2131

Title: NETWORK TRAFFIC MANAGEMENT BY A VIRUS/WORM MONITOR IN A DISTRIBUTED NETWORK

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first-class mail on April 7, 2005 in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Signed: _____

Agnes F. Spence

INFORMATION DISCLOSURE STATEMENT BEFORE FINAL ACTION OR NOTICE OF ALLOWANCE (37 CFR §§ 1.56 AND 1.97(c))

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The references listed in the attached PTO Form 1449, copies of the non-U.S. references are attached, may be material to examination of the above-identified patent application. Attached is a copy of the International Search Report. Please note reference White et al., "Anatomy of a Commercial-Grade Immune System" was previously cited in the Information Disclosure Statement filed on February 25, 2005. Applicants submit this reference in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make this citation of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this reference indeed constitutes prior art.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, or after three months of the filing date of this application, whichever

event occurred last, but it is believed before the mailing date of either: (i) a final action under §1.113 or (ii) a notice of allowance under §1.311, whichever occurs first.

Accompanying this Information Disclosure Statement is

☒ a statement as specified in 37 CFR 1.97(e); or

☐ the fee set forth in 37 CFR 1.17(p).

The undersigned hereby states:

☒ that each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application no more than three months prior to the filing of the Information Disclosure Statement; or

☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. TRNDP011).

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP

Michael J. Ferrazano
Registration No. 44,105

P.O. Box 70250
Oakland, CA 94612-0250

OIPE JC1 50
APR 1 1 2005
PATENT & TRADEMARK OFFICE

Form 1449 (Modified)	Atty Docket No.	Application No.:
	TRNDP011	10/683,579
Information Disclosure Statement By Applicant	Applicant: Liang et al.	
	Filing Date	Group
(Use Several Sheets if Necessary)	October 9, 2003	2131

U.S. Patent Documents

Examiner Initial	No.	Patent No.	Date	Patentee	Class	Sub-class	Filing Date
	A	5,623,600	4/22/97	Ji et al.			9/26/95
	B						
	C						
	D						
	E						
	F						

Foreign Patent or Published Foreign Patent Application

Examiner Initial	No.	Document No.	Publication Date	Country or Patent Office	Class	Sub-class	Translation	
							Yes	No
	J	EP 1 335 559 A2	13.08.2003	European Patent Office			X	
	K							
	L							
	M							
	N							

Other Documents

Examiner Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	O	
	P	
	Q	

Examiner	Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.